Paper39152241
Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.
Parsa S and 4 others. Cardiol Ther, 2024. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Milvexian: An Oral, Bioavailable Factor XIa Inhibitor. Papers, record 39152241. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39152241
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36030390 | A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. | Circulation | 2022 | https://conductscience.org/library/papers/36030390 | PubMed |
| 2 | 25482425 | Factor XI antisense oligonucleotide for prevention of venous thrombosis. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25482425 | PubMed |
| 3 | 30700128 | Intrinsic Pathway of Coagulation and Thrombosis. | Arterioscler Thromb Vasc Biol | 2019 | https://conductscience.org/library/papers/30700128 | PubMed |
| 4 | 34558200 | First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. | Clin Transl Sci | 2022 | https://conductscience.org/library/papers/34558200 | PubMed |
| 5 | 35647061 | Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35647061 | PubMed |
| 6 | 21870978 | Apixaban versus warfarin in patients with atrial fibrillation. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21870978 | PubMed |
| 7 | 37285155 | Analysis of Oral Anticoagulant Dosing and Adherence to Therapy Among Patients With Nonvalvular Atrial Fibrillation. | JAMA Netw Open | 2023 | https://conductscience.org/library/papers/37285155 | PubMed |
| 8 | 31935028 | Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. | JAMA | 2020 | https://conductscience.org/library/papers/31935028 | PubMed |
| 9 | 35385695 | Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. | Lancet | 2022 | https://conductscience.org/library/papers/35385695 | PubMed |
| 10 | 33471623 | Role of platelets in regulating activated coagulation factor XI activity. | Am J Physiol Cell Physiol | 2021 | https://conductscience.org/library/papers/33471623 | PubMed |
| 11 | 37101592 | Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis. | TH Open | 2023 | https://conductscience.org/library/papers/37101592 | PubMed |
| 12 | 36813377 | Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. | J Am Coll Cardiol | 2023 | https://conductscience.org/library/papers/36813377 | PubMed |
| 13 | 19717844 | Dabigatran versus warfarin in patients with atrial fibrillation. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19717844 | PubMed |
| 14 | 34985309 | Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. | Circulation | 2022 | https://conductscience.org/library/papers/34985309 | PubMed |
| 15 | 22993391 | In vivo roles of factor XII. | Blood | 2012 | https://conductscience.org/library/papers/22993391 | PubMed |
| 16 | 33541109 | Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation. | Circ Cardiovasc Qual Outcomes | 2021 | https://conductscience.org/library/papers/33541109 | PubMed |
| 17 | 34297496 | Abelacimab for Prevention of Venous Thromboembolism. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34297496 | PubMed |
| 18 | 34494428 | Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. | J Med Chem | 2022 | https://conductscience.org/library/papers/34494428 | PubMed |
| 19 | 17258668 | Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. | Lancet | 2007 | https://conductscience.org/library/papers/17258668 | PubMed |
| 20 | 36063821 | Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. | Lancet | 2022 | https://conductscience.org/library/papers/36063821 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39152241
GET https://conductscience.org/api/papers/v1/39152241/references?page=2